Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia

Leukemia Research

Volumn 33, Issue 9, 2009, Pages 1272-1275

  Hatzimichael, Eleftheria ^a   Benetatos, Leonidas ^a   Dasoula, Aggeliki ^a   Dranitsaris, George ^b   Tsiara, Stavroula ^a   Georgiou, Ioannis ^a   Syrrou, Maria ^c   Stebbing, Justin ^d   Coley, Helen M ^e   Crook, Tim ^d   Bourantas, Konstantinos L ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF IOANNINA   (Greece)

^d CHARING CROSS HOSPITAL   (United Kingdom)

^e UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

CDKN2A; Methylation; Multiple myeloma; TP73; Waldenstr m's macroglobulinemia

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P73;

ADULT; AGED; ANEMIA; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DEATH; DNA METHYLATION; FEMALE; GENE SILENCING; GENETIC RISK; HUMAN; HUMAN TISSUE; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; WALDENSTROEM MACROGLOBULINEMIA;

AGED; AGED, 80 AND OVER; BASE SEQUENCE; CPG ISLANDS; DNA METHYLATION; DNA PRIMERS; DNA-BINDING PROTEINS; FEMALE; GENE SILENCING; GENES, P16; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS; WALDENSTROM MACROGLOBULINEMIA;

EID: 67549142103     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.04.009     Document Type: Article

References (22)

1. Lopez J., Percharde M., Coley H.M., Webb A., and Crook T. The context and potential of epigenetics in oncology. Br J Cancer 100 (2009) 571-577
2. O'Nions J., Brooks L.A., Sullivan A., Bell A., Dunne B., Rozycka M., et al. Gusterson B and Crook T. p73 is over-expressed in vulval cancer principally as the Δ2 variant. Br J Cancer 85 (2001) 1551-1556
3. Zaika A.I., Slade N., Erster S.H., Sansome C., Joseph T.W., Pearl M., et al. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 196 (2002) 765-780
4. Liu M., Taketani T., Li R., Takita J., Taki T., Yang H.W., et al. Loss of p73 gene expression in lymphoid leukemia cell lines is associated with hypermethylation. Leuk Res 25 (2001) 441-447
5. Kawano S., Miller C.W., Gombart A.F., Bartram C.R., Matsuo Y., Asou H., et al. Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 94 (1999) 1113-1120
6. Siu L.L., Chan J.K., Wong K.F., and Kwong Y.L. Specific patterns of gene methylation in natural killer cell lymphomas: p73 is consistently involved. Am J Pathol 160 (2002) 59-66
7. Mateos M.V., Garcia-Sanz R., Lopez-Perez R., et al. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol 118 (2002) 1034-1040
8. Dib A., Barlogie B., Shaugnessy J.D., and Kuehl W.M. Methylation and expression of the p16INK4A tumor suppressor gene in multiple meyloma. Blood 109 (2007) 1337-1338
9. Wong D.J., Foster S.A., Galloway D.A., and Reid B.J. Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest. Moll Cell Biol 19 (1999) 5642-5651
10. Ushiku T., Chong J.M., Uozaki H., Hino R., Chang M.S., Sudo M., et al. P73 gene promoter methylation in Epstein-Barr virus-associated gastric carcinoma. Int J Cancer 120 (2007) 60-66
11. Smiraglia D.J., Smith L.T., Lang J.C., Rush L.J., Dai Z., Schuller D.E., et al. Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC). J Med Genet 40 (2003) 25-33
12. Domínguez G., García J.M., Peña C., Silva J., García V., Martínez L., et al. TAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol 24 (2006) 805-815
13. Ekmekci C.G., Gutiérrez M.I., Siraj A.K., Ozbek U., and Bhatia K. Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukaemia. Am J Hematol 77 (2004) 233-240
14. Garcia-Manero G., Daniel J., Smith T.L., Kornblau S.M., Lee M.S., Kantrjian H.M., et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 8 (2002) 2217-2224
15. Roman-Gomez J., Jimenez-Velasco A., Castillejo J.A., Agirre X., Barrios M., Navarro G., et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 104 (2004) 2492-2498
16. Chim C.S., Kwong Y.L., Fung T.K., and Liang R. Methylation profiling in multiple myeloma. Leuk Res 28 (2004) 379-385
17. Galm O., Wilop S., Reichelt J., Jost E., Gehbauer G., Herman J.G., et al. DANN methylation changes in multiple myeloma. Leukemia 18 (2004) 1687-1692
18. Seidl S., Ackermann J., Kaufmann H., Keck A., Nösslinger T., Zielinski C.C., et al. DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer 100 (2004) 2598-2606
19. San-Miguel J., García-Sanz R., and López-Pérez R. Analysis of methylation pattern in multiple myeloma. Acta Haematol 114 Suppl 1 (2005) 23-26
20. Gonzalez-Paz N., Chng W.J., McClure R.F., Blood E., Oken M.M., Van Ness B., et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 109 (2007) 1228-1232
21. Chim C.S., Liang R., Leung M.H., and Kwong Y.L. Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma. J Clin Pathol 60 (2007) 104-106
22. Rocco J.W., and Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 264 (2001) 42-55